Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Last week in January

<< Previous

Bullboard Posts

Next >>

Comment by IrishCanuckon Jan 24, 2021 9:52pm

203 Views

Post# 32372690

RE:RE:RE:RE:Last week in January

If you considered "ramping up in January" as anything more than discussions behind closed doors that you are not privy to then that is your own fault. Of course it was referring to advertising at the JP Morgan event and now we have Don Haut to help with those discussions plus the two hires in December.

Thinking is free, you should try it.

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project